For someone who has just seen his ideas for treating a crippling disease vindicated after years of rejection, Jonathan Edwards is remarkably self-effacing. Asked whether he feels he has brought hope to some of the millions with rheumatoid arthritis (RA), the 57-year-old rheumatolo-gist tends to look at his shoes or up at the ceiling. Edwards would much rather talk about where he plans to go next than to dwell on how his University College London (UCL) team's decade-long pursuit of an unfashionable idea has now led to a new RA therapy approved in the United States and in Europe.
展开▼